The PASSPORT clinical trial is researching whether a new investigational study drug can slow disease progression in study participants with PSP.
The main clinical trial lasts just over a year. It is divided into a 6-week screening period and a 52-week double-blind dosing period. Once this portion of the clinical trial concludes, there will also be an opportunity to participate in an open-label dosing period.
Taking part in this PSP clinical trial means visiting a trial clinic approximately every 4 weeks during the first year. This is when study participants can receive their dose of the investigational study drug. During visits, the clinical trial team will also carry out various tests to monitor how study participants are progressing.
(e.g., height and weight)
(e.g., temperature, breathing rate and pulse)
(to assess the status of PSP)
(to assess any changes in the brain)
(a painless way to look at the heart's electrical activity)
(to assess general well-being)
Please see the FAQ section to read about lumbar punctures.